Key result
Novel VEGFR-1 promoter variants linked to altered transcription are found exclusively in acute myocardial infarction.
Why the study?
VEGFR-1 gene variants may be involved in coronary artery disease including acute myocardial infarction, but their genetic and functional roles were not fully analyzed in large cohorts.
Do genetic variants in the VEGFR-1 gene promoter associate with acute myocardial infarction and alter transcriptional activity?
Case-Control (n=800)
No
Do genetic variants in the VEGFR-1 gene promoter associate with acute myocardial infarction and alter transcriptional activity?
p-value: p=<0.05
Genetic variants in the VEGFR-1 gene promoter identified in AMI patients alter transcriptional activity in vitro, suggesting a potential mechanistic role in the development of acute myocardial infarction.
VEGFR-1 variants may associate with AMI risk; hypothesis-generating and requires replication in prospective cohorts.
BACKGROUND: Coronary artery disease (CAD) including acute myocardial infarction (AMI) is a common complex disease caused by atherosclerosis. Vascular epithelial growth factor receptor-1 (VEGFR-1) stimulates angiogenesis and vascular permeability, and functions as a decoy to sequester VEGF and prevent initiation of intracellular signaling. VEGFR-1 knockout mice exhibit significantly higher mortality due to heart failure, cardiac hypertrophy, and cardiac dysfunction. An evident increase in macrophage infiltration and cardiac fibrosis are also observed after transverse aortic constriction. Therefore, VEGFR-1 gene variants may be involved in CAD. In this study, VEGFR-1 gene promoter was genetically and functionally analyzed in large cohorts of AMI patients and ethnic-matched controls. RESULTS: A total of 16 DNA sequence variants (DSVs) including six single-nucleotide polymorphisms (SNPs) were found in the VEGFR-1 gene promoter and 5'-untranslated region. Five novel DSVs and one SNP were only identified in AMI patients group. These DSVs and SNP significantly altered the transcriptional activity of the VEGFR-1 gene promoter in both HEK-293 and H9c2 cells (P < 0.05). Further electrophoretic mobility shift assay indicated that the DSVs and SNPs evidently affected the binding of transcription factors. CONCLUSIONS: The genetic variants in VEGFR-1 gene identified in AMI patients may alter the transcriptional activity of the VEGFR-1 gene promoter and change VEGFR-1 level, contributing to AMI development.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) conducted a case-control in Acute myocardial infarction (n=800). Genetic variants in the VEGFR-1 gene promoter vs. Wild-type VEGFR-1 gene promoter / healthy controls was evaluated on Identification of DNA sequence variants and their effect on transcriptional activity (p=<0.05). Five novel DNA sequence variants and one single-nucleotide polymorphism in the VEGFR-1 gene promoter were identified exclusively in acute myocardial infarction patients and significantly altered transcriptional activity (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: